FDA

News

Unswayed by a discount pledge, FDA adcomm rejects Lilly's PD...

FDA advisors have voted against approval of Eli Lilly and Innovent Biologics' cancer immunotherapy sintilimab, undermining hopes of a new, lower-priced option in the PD-1/PD-L1 inhibitor cl

News

FDA won't back Lilly's PD-1 antibody based on Chinese data a...

The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place on Thursday.

News

Sanofi claims FDA okay for drug to treat rare blood disorder...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

News

Califf pledges not to use 'revolving door' between FDA and i...

Robert Califf has made a series of commitments to try to win over senators reluctant to back his nomination as the next FDA commissioner, ahead of the deciding vote on his appointment.

News

FDA stifles Merck's cough drug gefapixant, asking for more d...

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close th

News

FDA clears Gilead's Veklury for COVID outpatients

The FDA has extended the emergency use authorisation for Gilead Sciences' antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug.

Unswayed by a discount pledge, FDA adcomm rejects Lilly's PD...

FDA won't back Lilly's PD-1 antibody based on Chinese data a...

Sanofi claims FDA okay for drug to treat rare blood disorder...

Califf pledges not to use 'revolving door' between FDA and i...

FDA stifles Merck's cough drug gefapixant, asking for more d...

FDA clears Gilead's Veklury for COVID outpatients

Harnessing the cell's own degradation machinery, with Benedi...

How to meet your physicians where they are online

FDA

Editor's Picks